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PHP1
EFFECT OF PRESCRIPTION COPAY ON MEDICATION
UTILIZATION
Gause D, Doyle JJ, Plauschinat C
Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: To assess impact of change in prescription copay
on change in medication utilization among patients taking three
common brand name medications: atorvastatin for dyslipide-
mia, pioglitazone for diabetes, or valsartan for hypertension.
METHODS: The Medstat MarketScan database was used to
identify patients taking a study drug (atorvastatin, pioglitazone,
or valsartan) in both 2003 and 2004. Patients had to have
continuous pharmacy coverage, at least one ﬁll in each year, and
be <65 years of age. The total copay for study drug was divided
by the total number of prescription ﬁlls to calculate average
copay for each patient in each year. Regression and partial cor-
relation analysis was used to estimate the association between
changes in copay and days supply, adjusting for age and gender.
RESULTS: Among 9342 valsartan patients, 4622 (49%) patients
had an increase in average copay and for these patients there was
on average 32 fewer days on drug in 2004 compared to valsartan
patients without an increase in copay (Spearman Rho = -0.14,
p-value < 0.01). There was also a negative association between
copay and days supply in patients receiving atorvastatin or
pioglitazone: 15 days less on pioglitazone and 18 days less on
atorvastatin for patients having an increase in average copay for
2004. Among patients using mail order prescriptions with ﬁlls
for >30 day supply the impact of copay on days supply was less
but still statistically signiﬁcant. CONCLUSION: Policy and
beneﬁt decision makers need to consider the impact of patient
copay on persistence for chronic diseases such as diabetes, hyper-
lipidemia, and hypertension.
PHP2
ADHERENCETO EVIDENCE-BASED GUIDELINES AND
MEDICATION COMPLIANCE FOR MULTIPLE CHRONIC
DISEASES IN A MANAGED CARE DATABASE
Burch SP, Priest JL, Cook CL, Cantrell CR
GlaxoSmithKline, Research Triangle Park, NC, USA
OBJECTIVE: To examine both adherence to treatment guide-
lines and medication compliance for commercially insured
patients with common chronic conditions including asthma,
chronic obstructive pulmonary disease (COPD), congestive heart
failure (CHF), coronary artery disease (CAD), depression, diabe-
tes, hyperlipidemia, and hypertension. METHODS: A retrospec-
tive cohort analysis of claims data was conducted using the
IHCIS Impact National Benchmark database representing >45
million lives. Patients were selected with evidence of disease
condition(s) between 2002 and 2006 who had 6 months of
data available post identiﬁcation with coverage through Decem-
ber 31, 2006. All analyses were conducted in 2006 and all costs
were annualized. Proportion of Days Covered was measured to
calculate compliance (between ﬁrst and last ﬁll) and persistence
(ﬁrst ﬁll through end of year) using an 80% cutoff. RESULTS:
For diabetes patients, 54% received no HbA1c test in 2006 and
only 33% received the ADA recommended 2 tests (measure
required patients to be continuously eligible during 2006 and
have prior evidence of diabetes). The percentage of patients
ﬁlling any acceptable disease speciﬁc prescription in 2006 was
80% for CHF, 68% for CAD, 60% for diabetes, 57% for depres-
sion, 44% for asthma and 36% for COPD. Of patients ﬁlling
medication, compliance ranged from 75% for diabetes and CHF
down to 49% and 36% for COPD and asthma respectively.
Persistence rates ranged from 77% for CAD to 23% for asthma.
CHF, COPD and CAD had the most expensive per-patient-per-
year total medical and pharmacy costs averaging $24,540,
$14,169, and $13,627 respectively. CONCLUSION: Across all
eight conditions, the percent of patients ﬁlling any acceptable
medication per treatment guidelines was low. Of those ﬁlling
medication, compliance and persistence rates were sub-optimal.
With the prevalence of chronic diseases increasing and the cost
associated rising dramatically, improvements in care per guide-
lines and medication compliance could potentially beneﬁt
patients, reduce costs and improve outcomes.
PHP3
ISTHERE AN ACCEPTABLE LEVEL OF MEDICATION
ADHERENCE? A REVIEW OF RETROSPECTIVE ADHERENCE
EVALUATION STUDIES
Visaria J, Seoane-Vazquez E, Schwartzbaum J, Szeinbach SL
The Ohio State University, Columbus, OH, USA
OBJECTIVE: The rationale for selection of a cut-point between
acceptable and unacceptable medication adherence has not been
previously evaluated. The objectives of this study were to
describe the dichotomized measures for medication adherence
and assess the rationale for selection of the cut-point.
METHODS: A systematic Medline review and examination of
studies assessing adherence using pharmacy claims from January
1997–June 2007 was performed. Studies containing partial or
incomplete methods for measuring adherence were excluded. A
sub-analysis of articles was conducted to determine the rationale
for selection of the cut-point. RESULTS: The review identiﬁed 98
studies with 103 measures of adherence. These studies investi-
gated adherence to cardiovascular drugs (39.8%), hormones and
synthetic substitutes (33.0%) and others (28.2%). The following
types of measures were used: medication possession ratio (MPR)
(45.6%), ﬁxed gap between reﬁlls (38.8%), proportion of days
covered (7.8%) and others (7.8%). Dichotomous measures were
used by 32.0% of the studies. A cut point was speciﬁed for
35.9% measures of adherence. The mean cutoff value was
76.0%  12.9%; with a median of 80.0%, and a range of
20.0%–90.0%. The sub-analysis contained 28 articles of which
35.7% refer to cut-points derived from previous clinical studies,
21.4% selected the cutpoint arbitrarily and 14.3% offered no
explanation, 7.1% provided clinical evidence, and 7.1%
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